5,390
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Tapentadol Prolonged Release in Patients with Chronic low back Pain: Real-World Data from the German Pain eRegistry

ORCID Icon, ORCID Icon, , , , & show all
Pages 211-227 | Received 21 Jun 2021, Accepted 20 Jul 2021, Published online: 11 Aug 2021

References

  • GBD 2017 Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet392, 1789–1858 (2018).
  • Hartvigsen J , HancockMJ , KongstedAet al. Low back pain 1. What low back pain is and why we need to pay attention. Lancet391, 2356–2367 (2018).
  • Itz CJ , GeurtsJW , van KleefM , NelemansP. Clinical course of non-specific low back pain: a systematic review of prospective cohort studies set in primary care. Eur. J. Pain.17, 5–15 (2013).
  • Freynhagen R , BaronR. The evaluation of neuropathic components in low back pain. Curr. Pain Headache Rep.13, 185–190 (2009).
  • Morlion B . Chronic low back pain: pharmacological, interventional and surgical strategies. Nat. Rev. Neurol.9, 462–473 (2013).
  • Baron R , BinderA , AttalN , CasaleR , DickensonAH , TreedeRD. Neuropathic low back pain in clinical practice. Eur. J. Pain.20, 861–873 (2016).
  • Foster NE , AnemaJR , CherkinDet al. Low back pain 2. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet391, 2368–2383 (2018).
  • Oliveira CB , MaherCG , PintoRZet al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur. Spine J.27, 2791–2803 (2018).
  • O’Brien T , ChristrupLL , DrewesAMet al. European Pain Federation position paper on appropriate opioid use in chronic pain management. Eur J Pain.21, 3–19 (2017).
  • Benyamin R , TrescotAM , DattaSet al. Opioid complications and side effects. Pain Physician.11, S105–S120 (2008).
  • Panchal SJ , Müller-SchwefeP , WurzelmannJI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int. J. Clin. Pract.61, 1181–1187 (2007).
  • Farmer AD , DrewesAM , ChiarioniGet al. Pathophysiology and management of opioid-induced constipation: European Expert Consensus statement. United European Gastroenterol. J.7, 7–20 (2019).
  • Lee AA , HaslerWL. Opioids and GI motility – friend or foe?Curr. Treat. Options Gastroenterol.14, 478–494 (2016).
  • Tzschentke TM , ChristophT , KögelBY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs.28, 319–329 (2014).
  • Baron R , EberhartL , KernKUet al. Tapentadol prolonged release for chronic pain: a review of clinical trials and 5 years of routine clinical practice data. Pain Pract.17, 678–700 (2017).
  • Buynak R , ShapiroDY , OkamotoAet al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin. Pharmacother.11, 1787–1804 (2010).
  • Steigerwald I , MüllerM , DaviesAet al. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, Phase 3b study. Curr. Med. Res. Opin.28, 911–936 (2012).
  • Gálvez R , SchäferM , HansG , FalkeD , SteigerwaldI. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, Phase 3b study. Adv. Ther.30, 229–259 (2013).
  • Baron R , LikarR , Martin-MolaEet al. Effectiveness of tapentadol prolonged release (PR) compared with oxycodone/naloxone PR for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, Phase 3b/4 study. Pain Pract.16, 580–599 (2016).
  • Baron R , JansenJP , BinderAet al. Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with oxycodone/naloxone PR in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, Phase 3b/4 trial. Pain Pract.16, 600–619 (2016).
  • Meng Z , YuJ , AcuffMet al. Tolerability of opioid analgesia for chronic pain: a network meta-analysis. Sci. Rep.7, 1995 (2017).
  • Wild JE , GrondS , KuperwasserBet al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract.10, 416–427 (2010).
  • Strick V . Management of severe chronic pain with tapentadol prolonged release - long-term data from pain specialists. Curr. Med. Res. Opin.30, 2085–2092 (2014).
  • Buynak R , RappaportSA , RodKet al. Long-term safety and efficacy of tapentadol extended release following up to 2 years of treatment in patients with moderate to severe, chronic pain: results of an open-label extension trial. Clin. Ther.37, 2420–2438 (2015).
  • Finco G , MuraP , MusuMet al. Long-term, prolonged-release oral tapentadol for the treatment of refractory chronic low back pain: a single-center, observational study. Minerva Medica.109, 259–265 (2018).
  • Gálvez Mateos R , SamperBernal D , TorresMorera LM , FerriCM , EsquiviasEscobar A. Long-term effectiveness and tolerability of pain treatment with tapentadol prolonged release. Pain Physician.24, E75–E85 (2021).
  • Cave A , KurzX , ArlettP. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin. Pharm. Ther.106, 36–39 (2019).
  • Bolislis WR , FayM , KühlerTC. Use of real-world data for new drug applications and line extensions. Clin. Ther.42, 926–938 (2020).
  • German Pain Association . Manual for the German Pain Questionnaire (in German). https://www.schmerzgesellschaft.de/fileadmin/pdf/DSF_Handbuch_2020.pdf
  • Tait RC , ChibnallJT , KrauseS. The pain disability index: psychometric properties. Pain40, 171–182 (1990).
  • Ware J Jr , KosinskiM , KellerSD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med. Care34, 220–233 (1996).
  • Freynhagen R , BaronR , GockelU , TölleTR. PainDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr. Med. Res. Opin.22, 1911–1920 (2006).
  • Cappelleri JC , BienenEJ , KoduruV , SadoskyA. Measurement properties of painDETECT by average pain severity. Clinicoecon. Outcomes Res.6, 497–504 (2014).
  • Rentz AM , YuR , Müller-LissnerS , LeyendeckerP. Validation of the bowel function index to detect clinically meaningful changes in opioid-induced constipation. J. Med. Econ.12, 371–383 (2009).
  • Ueberall MA , Müller-LissnerS , Buschmann-KrammC , BosseB. The bowel function index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J. Int. Med. Res.39, 41–50 (2011).
  • von Korff M , OrmelJ , KeefeFJ , DworkinSF. Grading the severity of chronic pain. Pain50, 133–149 (1992).
  • Ostelo RWJG , de VetHCW. Clinically important outcomes in low back pain. Best Pract. Res. Clin. Rheumatol.19, 593–607 (2005).
  • Díaz-Arribas MJ , Fernández-SerranoM , RoyuelaAet al. Minimally clinically important difference in quality of life for patients with low back pain. Spine42, 1908–1916 (2017).
  • Schmitt N , GerbershagenHU. The Mainz Staging System (MPSS) for chronic pain. Pain41(Suppl. 5), S484 (1990).
  • Überall MA . Poster presentation at the IASP 2021 Virtual World Congress on Pain: opioid-induced constipation in low back pain routine care with tapentadol.. The International Association for the Study of Pain.
  • Schröder W , DeVry J , TzschentkeTM , JahnelU , ChristophT. Differential contribution of opioid and nonadrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur. J. Pain14, 814–821 (2010).
  • Gonçalves L , FriendLV , DickensonAH. The influence of µ-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy. Eur. J. Pharmacol.749, 151–160 (2015).
  • Müller-Schwefe GHH , ÜberallMA. Pain and quality of life (in German). Gesundh Ökon. Qual. Manag.16, S20–S22 (2011).
  • Raffa RB , EllingC , TzschentkeTM. Does ‘strong analgesic’ equal ‘strong opioid’? Tapentadol and the concept of ‘μ-load’. Adv. Ther.35, 1471–1484 (2018).
  • Santos J , AlarcãoJ , FareleiraF , Vaz-CarneiroA , CostaJ. Tapentadol for chronic musculoskeletal pain in adults. Cochrane Database Syst. Rev. 20155, CD009923 (2015).
  • German Pain Association . Practice guideline opioid-induced constipation (in German) (2019). https://www.dgs-praxisleitlinien.de/index.php/leitlinien/oic
  • Treede RD , RiefW , BarkeAet al. Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the International Classification of Diseases (ICD-11). Pain160, 19–27 (2019).
  • Krenz P , WulfsbergJP , BruhnsF-L. Unfold Collective Intelligence! - opening up new potentials of value creation (in German). ZWF Zeitschrift für Wirtschaftlichen Fabrikbetrieb107(3), 152–157 (2012).